(Q40399200)

20 September 2017

title

Vaccination with virus-like particles protects mice from lethal infection of Rift Valley Fever Virus (English)

1 reference

Rift Valley fever phlebovirus

20 September 2017

main subject

0 references

Rift Valley fever

1 reference

based on heuristic

inferred from title

Rift Valley fever virus

object named as

Rift Valley Fever Virus

1 reference

7

1 reference

20 September 2017

3

Matthias Habjan

0 references

Clas Ahlm

series ordinal

6

object named as

Clas Ahlm

1 reference

20 September 2017

8

Göran Bucht

1 reference

20 September 2017

1

Jonas Näslund

1 reference

20 September 2017

Nina Lagerqvist

2

1 reference

20 September 2017

Ake Lundkvist

series ordinal

4

1 reference

20 September 2017

Magnus Evander

series ordinal

5

1 reference

20 September 2017

language of work or name

English

0 references

publication date

20 January 2009

1 reference

20 September 2017

number of pages

7

1 reference

based on heuristic

inferred from page(s)

published in

Virology

1 reference

20 September 2017

volume

385

1 reference

20 September 2017

issue

2

1 reference

20 September 2017

page(s)

409-415

1 reference

Epidemic Rift Valley fever in Saudi Arabia: a clinical study of severe illness in humans

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.12.012

Rift Valley fever: an uninvited zoonosis in the Arabian peninsula

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.12.012

Immunogenicity and protective efficacy of rotavirus 2/6-virus-like particles produced by a dual baculovirus expression vector and administered intramuscularly, intranasally, or orally to mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.12.012

NSs protein of Rift Valley fever virus blocks interferon production by inhibiting host gene transcription

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.12.012

RNA polymerase I-mediated expression of viral RNA for the rescue of infectious virulent and avirulent Rift Valley fever viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.12.012

Rift valley fever virus lacking the NSs and NSm genes is highly attenuated, confers protective immunity from virulent virus challenge, and allows for differential identification of infected and vaccinated animals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.12.012

Adverse response of non-indigenous cattle of European breeds to live attenuated Smithburn Rift Valley fever vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.12.012

Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.12.012

7 January 2021

Rift Valley fever virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.12.012

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.12.012

The NSm proteins of Rift Valley fever virus are dispensable for maturation, replication and infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.12.012

Virus-like particles: passport to immune recognition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.12.012

T7 RNA polymerase-dependent and -independent systems for cDNA-based rescue of Rift Valley fever virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.12.012

Efficient production of Rift Valley fever virus-like particles: The antiviral protein MxA can inhibit primary transcription of bunyaviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.12.012

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.12.012

Rescue of infectious rift valley fever virus entirely from cDNA, analysis of virus lacking the NSs gene, and expression of a foreign gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.12.012

Preparation and evaluation of a recombinant Rift Valley fever virus N protein for the detection of IgG and IgM antibodies in humans and animals by indirect ELISA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.12.012

A rift Valley fever vaccine trial. I. Side effects and serologic response over a six-month follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.12.012

Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.12.012

Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.12.012

TFIIH transcription factor, a target for the Rift Valley hemorrhagic fever virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.12.012

The N terminus of Rift Valley fever virus nucleoprotein is essential for dimerization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.12.012

Cross-reactive immune responses in mice after genetic vaccination with cDNA encoding hantavirus nucleocapsid proteins.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.12.012

Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.12.012

Human hepatitis B vaccine from recombinant yeast

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.12.012

The Rift Valley fever epizootic in Egypt 1977–1978 1. Description of the epizootic and virological studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.12.012

Characterization of clone 13, a naturally attenuated avirulent isolate of Rift Valley fever virus, which is altered in the small segment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.12.012

Kinetics of Rift Valley Fever Virus in experimentally infected mice using quantitative real-time RT-PCR.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.12.012

Immunogenicity of an inactivated Rift Valley fever vaccine in humans: a 12-year experience.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.12.012

Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.12.012

Neutralization of animal virus infectivity by antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.12.012

Rift Valley fever ocular manifestations: observations during the 1977 epidemic in Egypt

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.12.012

Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.12.012

Diva vaccines that reduce virus transmission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.12.012

Mapping of the mutations present in the genome of the Rift Valley fever virus attenuated MP12 strain and their putative role in attenuation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.12.012

Triple layered rotavirus VLP production: kinetics of vector replication, mRNA stability and recombinant protein production.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.12.012

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.12.012

Marburg virus-like particles protect guinea pigs from lethal Marburg virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.12.012

NSm protein of Rift Valley fever virus suppresses virus-induced apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.12.012

Production of monoclonal antibodies against Rift Valley fever virus Application for rapid diagnosis tests (virus detection and ELISA) in human sera

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.12.012

Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.12.012

Genetic reassortment of Rift Valley fever virus in nature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2008.12.012

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VIROL.2008.12.012

1 reference

20 September 2017

1 reference